Back to search

Peptide record

TPDB04903

Varv peptide F Antibacterial Anticancer Antifungal Antiparasitic Hemolysis Toxicity standard
29 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB04903
Varv peptide F
Antibacterial Anticancer Antifungal Antiparasitic Hemolysis Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 Peptipedia ACP740 _ACP240 AntiCP 2.0 CancerPPD 2.0 SATPdb dbACP iACP-DRLF Antifungipept APD_complete HemoPI Hemolytic2 PD_Hemolysis ToxinPred 3.0
standard
No
A 29-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, Peptipedia, ACP740 _ACP240, and other sources, with an available 3D structural model.
Sequence
GVPICGETCTLGTCYTAGCSCSWPVCTRN
Physicochemical Analysis
C122H192N34O41S6
DQHKMF
C
2983.43
5.90
1
1
7
-0
0.02
0.341
50.34
Mammalian: 30 hour Yeast: >20 hour E.coli: >10 hour
7365
246.86
15
Residue Composition
number
1
A
1
R
1
N
0
D
6
C
1
E
0
Q
4
G
0
H
1
I
1
L
0
K
0
M
0
F
2
P
2
S
5
T
1
W
1
Y
2
V
Amino Acid Distribution
A: 1 R: 1 N: 1 D: 0 C: 6 E: 1 Q: 0 G: 4 H: 0 I: 1 L: 1 K: 0 M: 0 F: 0 P: 2 S: 2 T: 5 W: 1 Y: 1 V: 2
Chemical Descriptors
29
C122H192N34O41S6
2983.43
5.90
-0
0.02
0.341
Free
L
Not Available
Free
Anticancer
Viola arvensis
Evidence Records 5 records
Evidence 1 Activity

Activity

Not Available
Anticancer

Target

Leukemia Cancer
Not Available
Not Available

Assay & Model

Not Available
Not Available

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
1999

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

HD50
Hemolysis
33.04 µM
[Ref.20580652] HD50=33.04µM against human type O red blood cells.

Target

human type O red blood cells

Source & Reference

Hemolytik APD_complete PD_Hemolysis
DRAMP4
J Nat Prod. 1999 Feb 62(2):283-286.##Mol Cancer Ther. 2002 Apr 1(6):365-369.##J Biol Chem. 2009 Apr 17 284(16):10672-83.

Other

Source Activity Label Source Definition
Hemolysis
APD_complete APD-derived hemolytic peptide annotation. Hemolytik experimentally validated hemolytic peptide annotation.
Evidence 3 Activity

Activity

50% Hemolysis
Toxicity
33.04 µM
Hemolytic Cytotoxic
50% Hemolysis | 33.04 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Isolation and characterization of cytotoxic cyclotides from Viola tricolor. | Peptides | 2010
Evidence 4 Activity

Activity

HD50
Toxicity
33.04 µM
Hemolytic Cytotoxic
Hemolytic_activity: [Ref.20580652] HD50=33.04µM against human type O red blood cells. | Cytotoxicity: [Ref.20580652] Cytotoxicity: U251(IC50=44.49µg/mL), MDA-MB-231(IC50>10µg/mL), A549(IC50>10µg/mL), DU145(IC50>10µg/mL), BEL-7402(IC50>10µg/mL).

Target

erythrocytes

Source & Reference

NA
DRAMP
J Nat Prod. 1999 Feb 62(2):283-286.##Mol Cancer Ther. 2002 Apr 1(6):365-369.##J Biol Chem. 2009 Apr 17 284(16):10672-83.
Evidence 5 Hemolysis

Activity

33.04 µM
HD50
[Ref.20580652] HD50=33.04µM against human type O red blood cells.
Hemolysis

Target

human type O red blood cells

Source & Reference

APD_complete HemoPI PD_Hemolysis
J Nat Prod. 1999 Feb 62(2):283-286.##Mol Cancer Ther. 2002 Apr 1(6):365-369.##J Biol Chem. 2009 Apr 17 284(16):10672-83.
DRAMP4
APD_complete PD_Hemolysis

Other

Source Activity Label Source Definition
Hemolysis
APD_complete APD-derived hemolytic peptide annotation.